NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF

NOVO NORDISK A S

Financials through fiscal 2025, year ended Dec 31, 2025

$38.42−0.41 (-1.06%)

Close on Oct 19, 2026

Community

Notes and questions about Novo Nordisk A S from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Novo Nordisk A S's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jan 31, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NVO.

Revenue growth6.4% · median 8.1%

Gross margin81.0% · median 70.4%

Advertisement
300 × 250